Janux Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.98 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $16.96Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1B Enterprise Value $1B Shares Outstanding 62.9M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Janux Therapeutics is a highly promising clinical-stage biopharmaceutical company leveraging its proprietary TRACTr, TRACIr, and ARM platforms to engineer tumor-activated immunotherapies. By selectively activating T cells in the tumor microenvironment, Janux's candidates aim to deliver potent anti-tumor activity while avoiding systemic toxicities like Cytokine Release Syndrome (CRS). The company's lead asset, JANX007, has demonstrated a potentially best-in-class profile in metastatic castration-resistant prostate cancer (mCRPC). Backed by a robust cash position of over $950 million and a validated platform through collaborations with Merck and Bristol Myers Squibb, Janux is well-positioned to advance its pipeline through key clinical milestones. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$14.00 Mean target$37.06 High · most bullish analyst$75.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $14.0020% Clinical trials for JANX007 or JANX014 encounter unexpected safety concerns or lack of durable efficacy, similar to the discontinued JANX008 program. High R&D cash burn accelerates, and partner collaborations fail to generate near-term milestone payments, leading to downward valuation pressure. Base CaseCentral scenario $36.0050% JANX007 continues steady clinical progress with favorable safety and efficacy profiles, maintaining its competitive edge in the mCRPC landscape. JANX011 and JANX014 advance through Phase 1 trials without major safety setbacks, and the company's cash runway remains sufficient to fund operations past 2027. Bull CaseUpside scenario $100.0030% JANX007 demonstrates exceptional efficacy and safety in Phase 1b taxane-naïve and combination cohorts, establishing it as a first-line standard of care in mCRPC. JANX011 successfully transitions into autoimmune indications with positive safety data, and the BMS collaboration yields further high-value development candidates, triggering substantial milestone payments. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |